Founded in 2012, ARMO BioSciences is a clinical-stage company developing immunotherapies focused on multiple difficult-to-treat oncology indications. The company's lead immunotherapy AM0010, a PEGylated form of recombinant human IL-10, primes the tumor micro-environment for immune-mediated therapies and has demonstrated durable clinical responses in several types of cancer, as both a single agent and in combination with standard-of-care chemotherapy or anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibodies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/11/16 | $50,000,000 | Series C |
Celgene Corporation Clough Capital Partners DAG Ventures GV HBM Healthcare Investments Industrial Investors Group NanoDimension OrbiMed Advisors | undisclosed |
| 08/31/17 | $67,000,000 | Series C-1 |
Celgene Corporation DAG Ventures Decheng Capital HBM Healthcare Investments NanoDimension OrbiMed Advisors Qiming Venture Partners  Quan Capital RTW Investments | undisclosed |
